Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation

References

• American Cancer Society: Cancer Facts & Figures 2014. Available: www.cancer.org, 2014
   Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008, 359:1367-1380; PMID:18815398; http://dx.doi.org/10.1056/NEJMra0802714
   PubMed Web of Science ®Google Scholar
• Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Jr., Lee JJ, Liu DD, Truong MT, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544-2555; PMID:15753462; http://dx.doi.org/10.1200/JCO.2005.02.477
   PubMed Web of Science ®Google Scholar
• Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Ann Rev Med 2003, 54:73-87; PMID:12471176; http://dx.doi.org/10.1146/annurev.med.54.101601.152202
   PubMed Web of Science ®Google Scholar
• Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002, 1:49-52; PMID:12086887; http://dx.doi.org/10.1016/S1535-6108(02)00027-2
   PubMed Web of Science ®Google Scholar
• Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 2009, 10:20-27; PMID:19289368; http://dx.doi.org/10.3816/CLC.2009.n.003
   PubMed Web of Science ®Google Scholar
• Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26:1472-1478; PMID:18349398; http://dx.doi.org/10.1200/JCO.2007.13.0062
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82:241-250; PMID:10454201; http://dx.doi.org/10.1016/S0163-7258(98)00045-X
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001, 37 Suppl 4:S9-15; http://dx.doi.org/10.1016/S0959-8049(01)00231-3
   PubMed Web of Science ®Google Scholar
• Westra WH. Early glandular neoplasia of the lung. Respir Res 2000, 1:163-169; PMID:11667981; http://dx.doi.org/10.1186/rr28
   PubMedGoogle Scholar
• Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005, 65:7568-7572; PMID:16140919
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 2008, 13:1166-1176; PMID:18997180; http://dx.doi.org/10.1634/theoncologist.2008-0108
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181; PMID:17318210; http://dx.doi.org/10.1038/nrc2088
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007, 25:587-595; PMID:17290067; http://dx.doi.org/10.1200/JCO.2006.07.3585
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73; PMID:15737014; http://dx.doi.org/10.1371/journal.pmed.0020073
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17; PMID:15696205; http://dx.doi.org/10.1371/journal.pmed.0020017
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909; PMID:16043828; http://dx.doi.org/10.1200/JCO.2005.02.857
   PubMed Web of Science ®Google Scholar
• Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734; PMID:18794081; http://dx.doi.org/10.1158/1078-0432.CCR-08-0646
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937; PMID:18093943; http://dx.doi.org/10.1073/pnas.0710370104
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043; PMID:17463250; http://dx.doi.org/10.1126/science.1141478
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genet 2012, 44:852-860; PMID:22751098; http://dx.doi.org/10.1038/ng.2330
   PubMed Web of Science ®Google Scholar
• Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006, 66:7854-7858; PMID:16912157; http://dx.doi.org/10.1158/0008-5472.CAN-06-1951
   PubMed Web of Science ®Google Scholar
• Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers–a different disease. Nat Rev Cancer 2007, 7:778-790; PMID:17882278; http://dx.doi.org/10.1038/nrc2190
   PubMed Web of Science ®Google Scholar
• Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene 2002, 21:7298-7306; PMID:12379874; http://dx.doi.org/10.1038/sj.onc.1205806
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647; PMID:15766527; http://dx.doi.org/10.1016/j.cell.2005.01.014
   PubMed Web of Science ®Google Scholar
• Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007, 17:1298-1307; PMID:17656095; http://dx.doi.org/10.1016/j.cub.2007.06.068
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134; PMID:17554337; http://dx.doi.org/10.1038/nature05939
   PubMed Web of Science ®Google Scholar
• Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007, 6:1586-1593; PMID:17554199; http://dx.doi.org/10.4161/cc.6.13.4436
   PubMed Web of Science ®Google Scholar
• Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26:731-743; PMID:17540598; http://dx.doi.org/10.1016/j.molcel.2007.05.017
   PubMed Web of Science ®Google Scholar
• Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05.010
   PubMed Web of Science ®Google Scholar
• Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, Einvik C. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011, 105:296-303; PMID:21654684; http://dx.doi.org/10.1038/bjc.2011.220
   PubMed Web of Science ®Google Scholar
• Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev 2009, 23:1743-1748; PMID:19574298; http://dx.doi.org/10.1101/gad.1812509
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756; PMID:15172979; http://dx.doi.org/10.1158/0008-5472.CAN-04-0637
   PubMed Web of Science ®Google Scholar
• Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007, 21:1025-1030; PMID:17437991; http://dx.doi.org/10.1101/gad.1540407
   PubMed Web of Science ®Google Scholar
• Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008, 320:97-100; PMID:18292307; http://dx.doi.org/10.1126/science.1154040
   PubMed Web of Science ®Google Scholar
• Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B, Hermeking H. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 2011, 10:M111 010462; http://dx.doi.org/10.1074/mcp.M111.010462
   PubMed Web of Science ®Google Scholar
• Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008, 27:5204-5213; PMID:18504438; http://dx.doi.org/10.1038/onc.2008.154
   PubMed Web of Science ®Google Scholar
• Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol 2014, 24:R762-776; PMID:25137592; http://dx.doi.org/10.1016/j.cub.2014.06.043
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012, 72:5576-5587; PMID:22964582; http://dx.doi.org/10.1158/0008-5472.CAN-12-2001
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011, 11:849-864; PMID:22113163; http://dx.doi.org/10.1038/nrc3166
   PubMed Web of Science ®Google Scholar
• Stahlhut C, Slack FJ. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med 2013, 5:111; PMID:24373327; http://dx.doi.org/10.1186/gm516
   PubMed Web of Science ®Google Scholar
• Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. Yale J Biol Med 2006, 79:131-140; PMID:17940623
   PubMedGoogle Scholar
• Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene 2014; PMID:25174400
   PubMed Web of Science ®Google Scholar
• Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011, 19:1116-1122; PMID:21427705; http://dx.doi.org/10.1038/mt.2011.48
   PubMed Web of Science ®Google Scholar
• Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010, 70:5923-5930; PMID:20570894; http://dx.doi.org/10.1158/0008-5472.CAN-10-0655
   PubMed Web of Science ®Google Scholar
• Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29:1580-1587; PMID:19966857; http://dx.doi.org/10.1038/onc.2009.445
   PubMed Web of Science ®Google Scholar
• Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012, 3:120; PMID:22783274; http://dx.doi.org/10.3389/fgene.2012.00120
   PubMedGoogle Scholar
• A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection [http://clinicaltrials.gov/show/NCT01829971], accessed 11/25/2014
   Google Scholar
• Zhao J, Kelnar K, Bader AG. In-depth analysis shows synergy between erlotinib and miR-34a. PloS One 2014, 9:e89105; PMID:24551227; http://dx.doi.org/10.1371/journal.pone.0089105
   PubMed Web of Science ®Google Scholar
• Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett 2014, 351:265-271; PMID:24983493; http://dx.doi.org/10.1016/j.canlet.2014.06.010
   PubMed Web of Science ®Google Scholar
• Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010, 28:585-593; PMID:20495549; http://dx.doi.org/10.1038/nbt.1640
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681; PMID:16968952
   PubMed Web of Science ®Google Scholar
• Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 1999, 17:2309-2315; PMID:10561292
   PubMed Web of Science ®Google Scholar
• Kelnar K, Peltier HJ, Leatherbury N, Stoudemire J, Bader AG. Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem 2014, 86:1534-1542; PMID:24397447
   PubMed Web of Science ®Google Scholar